Xspray Pharma has received another Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Dasynoc. This time, the remaining issues center on GMP observations at third-party manufacturer NerPharMa and additional data from consecutive commercial-scale batches. Xspray still
